NY-ALVAREZ-&-MARSAL
18.1.2023 07:01:35 CET | Business Wire | Press release
Leading global professional services firm Alvarez & Marsal (A&M) has announced the promotion of 85 professionals across Brazil, Benelux, Canada, Cayman Islands, China, France, Germany, India, Spain, United Arab Emirates, United Kingdom and the United States, to the position of Managing Director.
Tony Alvarez II and Bryan Marsal, A&M’s Co-Founders, stated, “Congratulations to all our newly promoted Managing Directors. Their commitment to help clients maximize value and drive change amid ongoing macro-economic challenges builds upon our legacy of operational excellence while advancing our results-oriented mission. Their proven ability to help solve for clients’ complex problems is critical to the firm’s success and growth moving forward.”
Henry Chambers, Hong Kong
Eden Chen, Shanghai
Sally Sun, Hong Kong
Pedro Bortolotto, São Paulo
Marcelo Compte, São Paulo
Rodrigo Domingues, São Paulo
Lilian Giorgi, São Paulo
Rodrigo Hong, São Paulo
Henrique Kanashiro, São Paulo
Rafael Mendonca Rodrigues, São Paulo
Fabio Missiato, São Paulo
Corporate Performance Improvement
Tiffany Guthrie, Houston
Mike Hall, San Francisco
John McKinnis, Dallas
Sam Rudkin, Atlanta
Kenneth Cochran, Charlotte
Jeffrey Dwyer, Chicago
Lakshman Lakshmanan, Dallas
Chad Lusk, Chicago
Joanna Rangarajan, New York
Global Disputes and Investigations
Lee Betteridge, London
Gary Foster, London
EMEA – Performance Improvement
Private Equity Performance Improvement
Nicola Barbini, London
Chris Gobby, London
Britta Mittler, Frankfurt
Till Prinz, Dusseldorf
Tim Veen, Munich
Gerardo Villalba Bello, Madrid
Ysabel Gaspar Zayco, London
Robert Bradbury, London
Dominic Roope, London
Jatin Arora, Dubai
Mark Bennett, Paris
Daran Hopper, London
Dirk Naujokat, Munich
Steve Trainor, London
Diana Wong, London
EMEA Restructuring
Barry Lynch, Grand Cayman
Helen Skeates, London
David Johnston, London
José Miguel Gómez Rivas, Madrid
Bill Ozturk, Dubai
Environmental, Social and Governance (ESG)
Stephanie Weiler, Chicago
JoyAnn Book, Phoenix
Bianca A. Briola Charlotte
David Nidetz, Detroit
Rich Rieger, Chicago
Anup Gandhi, Mumbai
Pranav Sheth, Mumbai
Infrastructure & Capital Projects
Sue Frost, Washington, D.C.
Alan Richard, Washington, D.C.
Private Equity Performance Group
Kent Edgerton, Nashville
Jana Gold, Washington, D.C.
Brad Howard, New York
Larry Thomas, Tampa
Klaus Weisenberger, San Francisco
Daniel Harlan, Washington, D.C
Restructuring & Turnaround (North America)
Taylor Atwood, Dallas
Matthew Davidson, Detroit
Chad Ellison, Calgary
Kamila Khairoullina, New York
Mark Sidorenkov, Phoenix
Jeff Sielinski, Detroit
Michael Zembillas, Atlanta
Simon Bernstein, New York
Stephanie Doughty, Houston
Michael Farkas, New York
Simon Gore, London
Jack Hollyman, London
Jac Emilio Martinez, Miami
Joseph Plati, New York
Brendan Sinnott, New York
Katya Umanskaya, Los Angeles
Global Transaction Advisory Group
Anuj Astir, New York
Nout Brugman, Amsterdam
David Cho, Chicago
Vitor Garcia, Sao Paulo
Jimmy Glenn, Atlanta
Nick Lynch, London
Jai Tandan, Mumbai
Rhett Taylor, Nashville
Nick Thoele, New York
Cedric Zana, Paris
Cole Corbin, New York
Steven Fischoff, Chicago
About Alvarez & Marsal
Companies, investors and government entities around the world turn to Alvarez & Marsal (A&M) for leadership, action and results. Privately held since its founding in 1983, A&M is a leading global professional services firm that provides advisory, business performance improvement and turnaround management services. When conventional approaches are not enough to create transformation and drive change, clients seek our deep expertise and ability to deliver practical solutions to their unique problems.
With over 7,000 people across five continents, we deliver tangible results for corporates, boards, private equity firms, law firms and government agencies facing complex challenges. Our senior leaders, and their teams, leverage A&M’s restructuring heritage to help companies act decisively, catapult growth and accelerate results. We are experienced operators, world-class consultants, former regulators and industry authorities with a shared commitment to telling clients what’s really needed for turning change into a strategic business asset, managing risk and unlocking value at every stage of growth.
To learn more, visit: AlvarezandMarsal.com. Follow A&M on LinkedIn, Twitter, and Facebook.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230117005828/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
SES Publishes FY2025 EU Taxonomy Restatement31.7.2026 07:30:00 CEST | Press release
SES today published a restatement of its FY2025 EU Taxonomy (Article 8) disclosure. The restatement updates the FY2025 EU Taxonomy disclosure included in the 2025 Annual Report and supersedes the previously published disclosure. The FY2025 EU Taxonomy Restatement is available on the SES website: https://www.ses.com/sites/ses_v2/files/investor-files/2026-07/EU_Taxonomy_Report_Restatement_2025.pdf Follow us on: X | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where they are. With integrated multi-orbit satellites and our global terrestrial network, we deliver resilient, seamless connectivity and the highest quality video content to those shaping what’s next. Following our Intelsat acquisition, we now offer more than 100 years of combined global industry l
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom